BrainScope Expands Board and Launches Advanced Deep Learning Platform to Enhance Brain Health Insights

BrainScope®, a leader in AI-enabled EEG technology for brain health assessment, today announced the launch of its next-generation deep learning platform. BrainScope developed and has commercialized the first FDA-cleared AI/machine learning medical device in the field of neurology. Building on that foundation in machine learning, BrainScope's new capabilities enhance its ability to deliver fast, objective, and clinically actionable insights across brain health conditions including concussion, stroke, and early Alzheimer's detection.

The integration of deep learning into BrainScope’s proprietary platform marks a major leap forward in automated EEG analysis. BrainScope’s new Large Neural Model platform brings many of the breakthroughs of Large Language Models (LLMs) to bear on EEG data, eliminating the need for specialized qEEG interpretation. This novel and proprietary approach enhances BrainScope’s first-in-class machine learning foundation, with the potential to significantly expand its utility across clinical care, research, and biopharma by enabling the development of more refined biomarkers to support precision-driven clinical trial recruitment, early diagnosis, personalized treatment, and improved patient outcomes.

To help guide the company as it expands its clinical program and commercial activities, BrainScope has announced key updates to its Board of Directors. Ralph Terkowitz, who has served on BrainScope’s Board since 2023, has been elected Chairman. A former General Partner at ABS Capital Partners, Terkowitz brings decades of experience helping technology companies grow and scale. He also serves on the Board of The 10,000 Brains Project and is Co-Chairman of The Robert Packard Center for ALS Research at Johns Hopkins. In his expanded role, Terkowitz will guide BrainScope’s continued growth and adoption of its AI-powered brain health platform.

Also joining the Board are Mike Genau, a seasoned global MedTech executive and former President of Medtronic’s Americas Region, and Brian Shea, who oversees healthcare investments and deal origination as Head of Origination at Aon Advantage Funds. Genau led a $7B business unit at Medtronic and brings deep expertise in scaling medical technologies and guiding commercial strategy. Shea offers a valuable perspective at the intersection of finance, healthcare, and technology.

“We’re thrilled to elevate Ralph to the Chairman role and honored to welcome Mike and Brian to our Board during this pivotal moment in BrainScope’s evolution,” said Laurie Silver, CEO of BrainScope. “Ralph has been an invaluable advisor as we’ve developed and launched our next-generation EEG-based Large Neural Model platform. Mike’s leadership in MedTech and Brian’s strategic investment insight will be beneficial as we scale commercially, drive clinical innovation in expanded markets, and bring in new investment partners. To reflect our expanded capabilities, we’ve also launched a new website showcasing our deep learning technology and broader brain health mission.”

“It’s exciting to take on the role of Chairman at such a transformative time,” said Ralph Terkowitz. “BrainScope is turning groundbreaking science into meaningful real-world impact, and has demonstrated success in using qEEG coupled with computational neuroscience as a diagnostic tool to aid in assessment of many neurological conditions including stroke, concussions, and early Alzheimer's. I look forward to helping the team expand this potentially groundbreaking opportunity.”

About BrainScope

BrainScope is a leading neurotechnology company with over 15 years of experience advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope’s initial commercial product remains the only point-of-care technology that objectively assesses head-injured patients for both brain bleeds and concussions. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and brain fog. For more information, please visit brainscope.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250611423351/en/

BrainScope’s new Large Neural Model platform brings many of the breakthroughs of Large Language Models to bear on EEG data, eliminating the need for specialized qEEG interpretation.